Literature DB >> 32144719

Trastuzumab Deruxtecan: First Approval.

Susan J Keam1.   

Abstract

Trastuzumab deruxtecan (ENHERTU®), a HER2-directed antibody and DNA topoisomerase I inhibitor conjugate, is being developed for the treatment of HER2-expressing solid tumours, including breast cancer, gastric cancer, colorectal cancer and non-small cell lung cancer by Daiichi Sankyo Company Ltd in collaboration with AstraZeneca. Based primarily on the results of the phase 2 DESTINY-Breast01 trial, trastuzumab deruxtecan was recently approved in the USA under accelerated approval for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. This article summarizes the milestones in the development of trastuzumab deruxtecan leading to this first approval.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32144719     DOI： 10.1007/s40265-020-01281-4

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  8 in total

1.  Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.

Authors:  Kohei Shitara; Hiroji Iwata; Shunji Takahashi; Kenji Tamura; Haeseong Park; Shanu Modi; Junji Tsurutani; Shigenori Kadowaki; Kensei Yamaguchi; Satoru Iwasa; Kaku Saito; Yoshihiko Fujisaki; Masahiro Sugihara; Javad Shahidi; Toshihiko Doi
Journal:  Lancet Oncol       Date:  2019-04-29       Impact factor: 41.316

2.  Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.

Authors:  Kenji Tamura; Junji Tsurutani; Shunji Takahashi; Hiroji Iwata; Ian E Krop; Charles Redfern; Yasuaki Sagara; Toshihiko Doi; Haeseong Park; Rashmi K Murthy; Rebecca A Redman; Takahiro Jikoh; Caleb Lee; Masahiro Sugihara; Javad Shahidi; Antoine Yver; Shanu Modi
Journal:  Lancet Oncol       Date:  2019-04-29       Impact factor: 41.316

Review 3.  The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy.

Authors:  Takashi Nakada; Kiyoshi Sugihara; Takahiro Jikoh; Yuki Abe; Toshinori Agatsuma
Journal:  Chem Pharm Bull (Tokyo)       Date:  2019       Impact factor: 1.645

4.  [fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification.

Authors:  Naoki Takegawa; Junji Tsurutani; Hisato Kawakami; Kimio Yonesaka; Ryoji Kato; Koji Haratani; Hidetoshi Hayashi; Masayuki Takeda; Yoshikane Nonagase; Osamu Maenishi; Kazuhiko Nakagawa
Journal:  Int J Cancer       Date:  2019-05-24       Impact factor: 7.396

5.  DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.

Authors:  Yusuke Ogitani; Tetsuo Aida; Katsunobu Hagihara; Junko Yamaguchi; Chiaki Ishii; Naoya Harada; Masako Soma; Hiromi Okamoto; Masataka Oitate; Shingo Arakawa; Takehiro Hirai; Ryo Atsumi; Takashi Nakada; Ichiro Hayakawa; Yuki Abe; Toshinori Agatsuma
Journal:  Clin Cancer Res       Date:  2016-03-29       Impact factor: 12.531

6.  DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance.

Authors:  Naoki Takegawa; Yoshikane Nonagase; Kimio Yonesaka; Kazuko Sakai; Osamu Maenishi; Yusuke Ogitani; Takao Tamura; Kazuto Nishio; Kazuhiko Nakagawa; Junji Tsurutani
Journal:  Int J Cancer       Date:  2017-07-12       Impact factor: 7.396

7.  Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.

Authors:  Shanu Modi; Cristina Saura; Toshinari Yamashita; Yeon Hee Park; Sung-Bae Kim; Kenji Tamura; Fabrice Andre; Hiroji Iwata; Yoshinori Ito; Junji Tsurutani; Joohyuk Sohn; Neelima Denduluri; Christophe Perrin; Kenjiro Aogi; Eriko Tokunaga; Seock-Ah Im; Keun Seok Lee; Sara A Hurvitz; Javier Cortes; Caleb Lee; Shuquan Chen; Lin Zhang; Javad Shahidi; Antoine Yver; Ian Krop
Journal:  N Engl J Med       Date:  2019-12-11       Impact factor: 91.245

8.  Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.

Authors:  Yusuke Ogitani; Katsunobu Hagihara; Masataka Oitate; Hiroyuki Naito; Toshinori Agatsuma
Journal:  Cancer Sci       Date:  2016-06-22       Impact factor: 6.716
  8 in total
  38 in total

Review 1.  Mechanisms contributing to ado-trastuzumab emtansine-induced toxicities: a gateway to better understanding of ADC-associated toxicities.

Authors:  Yukinori Endo; Nishant Mohan; Milos Dokmanovic; Wen Jin Wu
Journal:  Antib Ther       Date:  2021-03-16

2.  Antibody-drug conjugate MORAb-202 exhibits long-lasting antitumor efficacy in TNBC PDx models.

Authors:  Keiji Furuuchi; Katherine Rybinski; James Fulmer; Tomoyuki Moriyama; Brian Drozdowski; Allis Soto; Shawn Fernando; Kerrianne Wilson; Andrew Milinichik; Mary Lou Dula; Keigo Tanaka; Xin Cheng; Earl Albone; Toshimitsu Uenaka
Journal:  Cancer Sci       Date:  2021-05-01       Impact factor: 6.716

3.  The cytotoxic conjugate of highly internalizing tetravalent antibody for targeting FGFR1-overproducing cancer cells.

Authors:  Marta Poźniak; Natalia Porębska; Mateusz Adam Krzyścik; Aleksandra Sokołowska-Wędzina; Kamil Jastrzębski; Martyna Sochacka; Jakub Szymczyk; Małgorzata Zakrzewska; Jacek Otlewski; Łukasz Opaliński
Journal:  Mol Med       Date:  2021-05-07       Impact factor: 6.354

Review 4.  Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors.

Authors:  Alice Indini; Erika Rijavec; Francesco Grossi
Journal:  Int J Mol Sci       Date:  2021-04-30       Impact factor: 5.923

5.  Targeted delivery of heat shock protein 90 inhibitors prevents growth of HER2-positive tumor.

Authors:  Kwang Suk Lim; Daniel Y Lee; Seungmin Han; David A Bull; Young-Wook Won
Journal:  Biomaterials       Date:  2021-04-19       Impact factor: 15.304

Review 6.  Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape.

Authors:  E Adams; H Wildiers; P Neven; K Punie
Journal:  ESMO Open       Date:  2021-07-02

7.  Rapid and robust cysteine bioconjugation with vinylheteroarenes.

Authors:  Hikaru Seki; Stephen J Walsh; Jonathan D Bargh; Jeremy S Parker; Jason Carroll; David R Spring
Journal:  Chem Sci       Date:  2021-06-07       Impact factor: 9.825

Review 8.  Mechanisms of Therapeutic Antitumor Monoclonal Antibodies.

Authors:  Li-Chung Tsao; Jeremy Force; Zachary C Hartman
Journal:  Cancer Res       Date:  2021-06-18       Impact factor: 13.312

Review 9.  Stepping forward in antibody-drug conjugate development.

Authors:  Yiming Jin; Megan A Schladetsch; Xueting Huang; Marcy J Balunas; Andrew J Wiemer
Journal:  Pharmacol Ther       Date:  2021-06-24       Impact factor: 12.310

Review 10.  The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively.

Authors:  Wen-Qian Li; Han-Fei Guo; Ling-Yu Li; Yong-Fei Zhang; Jiu-Wei Cui
Journal:  Cancer Med       Date:  2021-06-24       Impact factor: 4.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.